Ocugen shares are trading lower after the company announced topline 12-month data from its Phase 2 ArMaDa clinical trial evaluating OCU410 for geographic atrophy secondary to dry age-related macular degeneration. Key findings include a 31% reduction in lesion growth in the optimal dose group compared to control.